NCI trials for February
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – 10114
Phase I Trial of 5-Aza-4′-Thio-2′-Deoxycytidine (Aza-TdC) in Patients with Advanced Solid Tumors
National Cancer Institute Developmental Therapeutics Clinic
Doroshow, James H.
(240) 781-3320
Phase I/II – ADVL1614
A Phase 1/2 Study of VX15/2503 (IND#136181) in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors
COG Phase 1 Consortium
Greengard, Emily G.
(612) 626-2378
Phase I/II – EA9152
A Phase IB/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia
ECOG-ACRIN Cancer Research Group
Palmisiano, Neil David
(215) 503-0432
Phase II – 10100
A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination with Atezolizumab Compared to Atezolizumab Alone in Subjects with Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Platinum-Based Treatment is Not an Option
City of Hope Comprehensive Cancer Center LAO
Quinn, David Ian
(323) 865-3956
Phase II – 10104
A Randomized Phase 2 Study of Cabozantinib in Combination with Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
University Health Network Princess Margaret Cancer Center LAO
Lheureux, Stephanie
(416) 946-4501 X 2415
Phase II – A091605
A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma
Alliance for Clinical Trials in Oncology
Luke, Jason John
(617) 632-6588
Phase II – AMC-103
A Phase 2 Evaluation of VGX-3100, a Synthetic DNA Immunotherapy Targeting Human Papillomavirus 16 and 18 E6 and E7 Proteins, for Anal High-Grade Squamous Intraepithelial Lesions (HSIL) in HIV-Positive Individuals
AIDS Malignancy Consortium
Wang, Chia-Ching (Jackie)
(415) 476-4082 X 146
Phase II – EA3163
Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
ECOG-ACRIN Cancer Research Group
Saba, Nabil F.
(404) 778-1900
Phase II – EAE161
Perfusion CT to Predict Progression-Free Survival and Response Rate in Bevacizumab and Paclitaxel Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma
ECOG-ACRIN Cancer Research Group
Lee, Susanna I.
(617) 643-2009
Phase II – S1400K
A Phase II Study of ABBV-399 (Process II) in Patients with C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)
SWOG
Waqar, Saiama Naheed
(314) 362-5737
Phase II – S1702
A Phase II Study of Isatuximab (SAR650984) for Patients with Previously Treated AL Amyloidosis
SWOG
Scott, Emma Catherine
(503) 494-2398
Phase Other – AALL17B2-Q
Predicting Relapse Based on Deep Single-Cell Phenotyping at Diagnosis
Children’s Oncology Group
Davis, Kara Lynn
(650) 724-8073
Phase Other – ARST17B2-Q
Germline Genetic Landscape of Pediatric Rhabdomyosarcoma
Children’s Oncology Group
Lupo, Philip
(713) 798-2960
NCI Community Oncology Research Program (NCORP) clinical trials:
Phase Other – EAQ162CD
Longitudinal Assessment of Financial Burden in Patients with Colon or Rectal Cancer Treated with Curative Intent
ECOG-ACRIN Cancer Research Group
Kircher, Sheetal Mehta
(312) 695-6180
Phase Other – WF-20817CD
Implementation of Smoking Cessation Services within NCI NCORP Community Sites with Organized Lung Cancer Screening Programs
Wake Forest NCORP Research Base
Foley, Kristie L.
(336) 713-5084
